Skip to content

Study · Not a test of the peptide alone · 2025

1 result

Nonoperative Case of Acute Type A Aortic Dissection in a Young Patient.

El-Andari R, Graham MM, Wiens EJ

JACC. Case reports1 Jul 2025

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 33-year-old man with super obesity and acute type A aortic dissection, semaglutide coupled with physical therapy was followed by weight loss, with a body mass index of 59 kg/m2 at 4 months.

    In plain wordsIn one man with severe obesity and an aortic dissection, weight fell when semaglutide was used together with physical therapy.

    Outcome
    DecreaseBody mass index during acute illness
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The use of semaglutide during acute illness has not been previously reported, but coupled with physical therapy facilitated weight loss.
    2 context sentences
    Summary · context
    The patient continues making progress 4 months later with a current body mass index of 59 kg/m2.
    Summary · context
    A 33-year-old man with acute type A aortic dissection was ineligible for surgery owing to super obesity (body mass index: 77 kg/m2).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.